Guardant360 Liquid is the first and only commercially available liquid biopsy to unlock genomics and epigenomics from a single input.
The first and only test to deliver genomic and epigenomic insights
in one.1*
CHIP, clonal hematopoiesis of indeterminate potential;MSI, microsatellite instability; TMB, tumor mutation burden.
*Guardant360 is guideline-complete for genomic biomarkers.
†Includes TERT promoter region.
Important note: Guardant360 Liquid is developed as Laboratory Developed Tests (LDTs) and its performance characteristics determined by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Product availability may vary depending on country/region. Guardant360 Liquid is not approved nor marketed in EU.
EUAA
Home Oncology Portfolio Partnerships European Policy
